Telemedicine Startup Funding

What are all the funding deals in the telemedicine market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play telemedicine companies between August 2025 and July 2026. We count as “pure-play” telemedicine companies those focused on remote clinical care delivery through video, messaging, digital triage, virtual specialty care, telepsychiatry, remote prescribing, or telehealth infrastructure.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source.

How active has fundraising been in the telemedicine market?

As of July 2026, fundraising in the telemedicine market has been active but uneven. Over the past 12 months, pure-play telemedicine companies raised 19 disclosed equity rounds and $779.62M in total capital.

That works out to an average of 1.58 deals per month, with a median of 1.50 deals per month. The telemedicine market was therefore consistently visible, but not continuously busy.

Monthly capital was much more volatile than monthly deal count. The average month produced $64.97M of funding, while the median month produced only $30M.

February 2026 was the strongest month, with $320M raised across 3 deals. That month alone included Talkiatry and Midi Health, showing how one or two scaled rounds can reshape the whole period.

How concentrated has fundraising been in the telemedicine market?

As of July 2026, fundraising in the telemedicine market has been highly concentrated. Over the past 12 months, the largest deal represented 26.94% of all disclosed capital, while the top 3 deals represented 52.59%.

The top 5 deals reached 67.47% of total capital, and the top 10 deals reached 85.23%. This means more than half of the market’s funding came from just three companies.

This concentration matters because it limits what total funding says about the whole telemedicine market. A headline about $779.62M raised is partly a story about a few large platforms.

Removing rounds above $50M cuts total capital from $779.62M to $292.62M. That is a 62.5% reduction, which confirms how dependent the market is on large financings.

How much of the telemedicine funding signal is driven by outliers?

As of July 2026, a large part of the telemedicine funding signal is driven by outliers. Over the past 12 months, four rounds above $50M represented only 21.05% of deals but $487M of capital.

Talkiatry alone raised $210M, equal to 26.94% of the market’s disclosed capital. Midi Health and Nourish each added $100M rounds, reinforcing the same pattern.

The market’s average round size was $41.03M, but the median was only $25M. That gap shows that average deal size should not be read as the normal funding level.

The cleaner benchmark is the middle of the market. Nine deals sat in the $20M to $50M range, which makes that bucket a better signal of recurring institutional conviction.

Is the telemedicine market broad with many targets, or narrow with few fundable companies?

As of July 2026, the telemedicine market looks narrow rather than broadly distributed. Over the past 12 months, the dataset includes 19 deals across 19 unique companies.

The category mix makes that narrowness clearer. Specialist Telehealth and Telepsychiatry together accounted for 12 of 19 deals and $609M of capital.

Basic video-consultation platforms were almost absent from the funding picture. Only MedySeva appeared in that category, with a $0.45M seed round in Asia-Pacific.

This suggests that investors are no longer financing telemedicine as a generic access channel. They are financing remote care when it is attached to specialist supply, clinical depth, reimbursement, or enterprise infrastructure.

Is telemedicine mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the telemedicine market is mostly a late-stage scaling market. Over the past 12 months, Series B and later rounds, including Growth Equity, captured $587M, or 75.30% of total capital.

Early-stage rounds were present, but they did not drive the market. Seed and Series A deals represented 7 of 19 rounds, but only $104.45M, or 13.40% of disclosed capital.

The Series D+ bucket alone captured $310M from just 2 deals. Talkiatry and Midi Health therefore made late-stage survivorship one of the clearest signals in the dataset.

This does not mean new telemedicine companies cannot raise. Avela Health and Blossom Health were marked as first financings, but most capital still favored companies with prior proof points.

Which categories attract the most investor attention in telemedicine?

As of July 2026, Specialist Telehealth attracted the most investor attention in the telemedicine market. Over the past 12 months, the category produced 9 of 19 deals and raised $344M.

That 47.37% deal share matters because it is broad, not just one company. The category includes virtual dementia care, women’s health, pediatrics, cardiometabolic care, neurology, autism therapy, and nutrition.

Telepsychiatry was second by capital, with $265M raised across 3 deals. Its deal count was smaller, but Talkiatry’s $210M round made the category disproportionately important.

Telehealth Infrastructure also remained meaningful, with 3 deals and $129.5M raised. Caregility, MD Integrations, and KeyCare show that enterprise and hospital-facing telemedicine infrastructure still attracts institutional funding.

Which categories attract disproportionately large checks in the telemedicine market?

As of July 2026, Telepsychiatry attracted the most disproportionately large checks in the telemedicine market. Over the past 12 months, it represented 15.79% of deals but 33.99% of disclosed capital.

That gives Telepsychiatry a capital share to deal share ratio of 2.15. In plain terms, the category raised more than twice the capital its deal count would imply.

The reason is Talkiatry. Its $210M Series D+ made telepsychiatry look like a scaled category rather than only a mental-health access niche.

Telehealth Infrastructure was closer to parity, with 15.79% of deals and 16.61% of capital. Specialist Telehealth was also near parity, with 47.37% of deals and 44.12% of capital.

Which geographies matter most for fundraising in the telemedicine market?

As of July 2026, North America mattered most for fundraising in the telemedicine market. Over the past 12 months, it accounted for 16 of 19 deals and $763.50M of disclosed capital.

That equals 84.21% of deals and 97.93% of total capital. The telemedicine market is therefore heavily shaped by U.S. reimbursement, employer benefits, health-system adoption, and specialist shortages.

The rest of the world appeared, but at much smaller check sizes. The Middle East contributed one $15M TruDoc round, Africa contributed one $0.67M Mobihealth round, and Asia-Pacific contributed one $0.45M MedySeva round.

Europe had no qualified pure-play telemedicine round in this dataset. That should be read as a funding-sample signal, not as proof that European digital health had no activity.

Is the telemedicine opportunity set broad or concentrated in one hub?

As of July 2026, the telemedicine opportunity set is concentrated in one main funding hub. Over the past 12 months, North America captured nearly all disclosed capital in the telemedicine market.

North America’s dominance was stronger on dollars than on deal count. The region held 84.21% of deals, but 97.93% of total capital.

Non-North American rounds were visible but small. Together, the Middle East, Africa, and Asia-Pacific represented 15.79% of deals but only 2.07% of capital.

This creates a bifurcated market. U.S. specialist and enterprise telemedicine platforms can raise $20M to $210M, while emerging-market telemedicine rounds remain sub-$1M to low-teens millions.

Is telemedicine a market of small experiments or scaled financings?

As of July 2026, telemedicine is not mainly a market of small experiments. Over the past 12 months, the median disclosed round size was $25M, and 13 of 19 deals were $20M or larger.

The largest bucket was $20M to $50M, with 9 deals. That bucket is important because it reflects recurring institutional financing without relying only on megarounds.

Four deals were above $50M, including one above $100M. Those large rounds accounted for most dollars, but not most deal activity.

Small rounds still existed, especially outside North America. MedySeva and Mobihealth were both below $1M, showing that global telemedicine need does not automatically translate into venture-scale capital.

Who are the investors that appear the most in telemedicine fundraising?

As of July 2026, no investor clearly appeared in more than one qualified telemedicine funding round. Over the past 12 months, the dataset did not show a confirmed repeat investor across multiple deals using first-hand or tier-1 public sources.

This is important because the market does not look like a single investor-led funding wave. It looks more like a set of company-specific rounds across psychiatry, specialty care, infrastructure, and virtual primary care.

There is one caveat. Menlo Ventures appears in the ecosystem around Cartwheel Care and led Nourish’s Series C, but the Cartwheel source did not clearly confirm Menlo as a new participant in the August 2025 financing.

For that reason, Menlo is not counted as a confirmed repeat investor. The stricter reading is better because it avoids overstating investor concentration when source evidence is incomplete.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.